Other official information and services: www.belgium.be  belgium

Antidepressants

  • Key figures
  • Data
  • Graphics
  • Comments
PRESCRIBERS
Main prescribers: General practitioners 78.55%
RATE OF USE
Annual consumption (DDD) 360,069,409
Standardised rate of use (per 100,000 insured persons) 3,140,548.16
Average annual consumption per patient (DDD) 284.05
% Insured persons concerned 11.06%
Approximate % DDD issued outside the insurance 7.13%
% Patients with more than 3 times the average consumption 3.95%
POPULATION
Median age 58 years
Max/min ratio of the median age (by district) 1.14
Percentage of women 67.49%
Ratio Preferential scheme/General scheme 2.01
CONSUMPTION TRENDS (DDD)
Trend 2011-2021 1.83%
Trend 2011-2019 1.63%
Trend 2019-2021 2.62%
GEOGRAPHICAL VARIATIONS
Coefficient of variation 2011-2013 17.86
Coefficient of variation 2019-2021 13.45
Max/min ratio of consumption (DDD per 100,000 insured persons, by region) 1.37
Max/min ratio of consumption ( DDD per 100,000 insured persons, by district) 1.79
DIRECT EXPENDITURE
Annual expenditure charged to the insurance 82,770,571€
Average annual expenditure per insured person 7.22 €
Average patient share (under insurance) 22.05%
Max/min ratio of expenditure per insured person (by region) 1.39
Max/min ratio of expenditure per insured person (by disctrict) 1.73
% “Low-cost” medication 94.68%


On this table, when a statistical test has been performed, the data showing a significant difference is displayed on an yellow background, otherwise on a grey background.

+ - ATC codes selected for analysis Click to collapse

CODES LABEL LABEL ATC-5
N06AA02 IMIPRAMINE INHIBITEURS NON SELECTIFS DE LA RECAPTURE DE MONOAMINES
N06AA04 CLOMIPRAMINE INHIBITEURS NON SELECTIFS DE LA RECAPTURE DE MONOAMINES
N06AA09 AMITRIPTYLINE INHIBITEURS NON SELECTIFS DE LA RECAPTURE DE MONOAMINES
N06AA10 NORTRIPTYLINE INHIBITEURS NON SELECTIFS DE LA RECAPTURE DE MONOAMINES
N06AA16 DOSULEPINE INHIBITEURS NON SELECTIFS DE LA RECAPTURE DE MONOAMINES
N06AA21 MAPROTILINE INHIBITEURS NON SELECTIFS DE LA RECAPTURE DE MONOAMINES
N06AB03 FLUOXETINE INHIBITEURS SELECTIFS DE LA RECAPTURE DE LA SEROTONINE
N06AB04 CITALOPRAM INHIBITEURS SELECTIFS DE LA RECAPTURE DE LA SEROTONINE
N06AB05 PAROXETINE INHIBITEURS SELECTIFS DE LA RECAPTURE DE LA SEROTONINE
N06AB06 SERTRALINE INHIBITEURS SELECTIFS DE LA RECAPTURE DE LA SEROTONINE
N06AB08 FLUVOXAMINE INHIBITEURS SELECTIFS DE LA RECAPTURE DE LA SEROTONINE
N06AB10 ESCITALOPRAM INHIBITEURS SELECTIFS DE LA RECAPTURE DE LA SEROTONINE
N06AG02 MOCLOBEMIDE INHIBITEURS DE LA MONOAMINE OXYDASE DE TYPE A
N06AX03 MIANSERINE AUTRES ANTIDEPRESSEURS
N06AX05 TRAZODONE AUTRES ANTIDEPRESSEURS
N06AX11 MIRTAZAPINE AUTRES ANTIDEPRESSEURS
N06AX12 BUPROPION AUTRES ANTIDEPRESSEURS
N06AX16 VENLAFAXINE AUTRES ANTIDEPRESSEURS
N06AX18 REBOXETINE AUTRES ANTIDEPRESSEURS
N06AX21 DULOXETINE AUTRES ANTIDEPRESSEURS

The labels on a blue background are the medicines that exist under the status "low cost".
The codes mentioned above can be used in rates and expenses, or only in expenses. We invite you to consult the full report for more information.

Click here to see the graph illustrating the evolution of the breakdown by volume of ATC codes used for the rates.

+ - Population selection Click to collapse

No selection

+ - Analysis period Click to collapse

2021

  • ATC codesATC codes
  • Age Gender CVAge, gender and CV
  • Rates by sexRates by sex
  • Reimbursement rateReimbursement rate
  • TrendsTrends by region
  • Trends breakTrends break
  • Dot PlotDot Plot
  • Funnel PlotFunnel plot
  • Provincial consumptionDDD per patient by province
  • DDD patientQuantity per patient
  • MapDistribution map
  • Low-costLow-cost DDD

WE ARE INTERESTED IN YOUR OPINION

Do you have any experience in this area ? We listen to you !

Send us an email

Download the full report
 Download the methodology